Price
$0.6198
Decreased by -3.38%
Dollar Volume
91.84 K
ADR%
10.42
Earnings Report Date (estimate)
Feb 22, 23 (-0.59)
Market Cap.
24.14 M
Shares Float
25.54 M
Shares Outstanding
38.94 M
Beta
1.79
Price / Earnings
-0.19
BPR
6.23
20D Range
0.44 0.70
50D Range
0.33 1.31
200D Range
0.33 5.28
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 7, 22 -0.65
Increased by +4.41%
-0.65
Aug 4, 22 -0.93
Decreased by -50.00%
-0.78
Decreased by -19.23%
May 9, 22 -1.10
Decreased by -89.66%
-0.75
Decreased by -46.67%
Feb 24, 22 -0.78
Decreased by -105.26%
-0.66
Decreased by -18.18%
Nov 10, 21 -0.68
Decreased by -41.67%
-0.62
Decreased by -9.68%
Aug 10, 21 -0.62
Increased by +44.14%
-0.60
Decreased by -3.33%
May 13, 21 -0.58
Increased by +90.50%
-0.75
Increased by +22.67%
Mar 19, 21 -0.38 -0.47
Increased by +19.15%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-25.21 M
Increased by +3.02%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-35.95 M
Decreased by -52.12%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-42.58 M
Decreased by -108.07%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-30.20 M
Decreased by -58.29%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-25.99 M
Decreased by -54.78%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-23.63 M
Decreased by -53.65%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-20.46 M
Decreased by -33.64%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-19.08 M
Decreased by -142.48%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.